Status:
RECRUITING
Newborn Genomics Programme
Lead Sponsor:
Liggins Institute
Conditions:
Genetic Disease
Newborn Morbidity
Eligibility:
All Genders
Up to 2 years
Brief Summary
Genomic methods can significantly contribute to all facets of precision medicine, from diagnosis to prevention, therapeutic intervention, and management of acute and chronic illnesses. DNA based metho...
Eligibility Criteria
Inclusion
- Acutely ill inpatient
- Admitted to NICU or PICU between April 2023 - March 2026
- Within 1 week of hospitalization or within 1 week of development of abnormal response to standard therapy for an underlying condition
- Suspected genetic condition, without a clear non-genetic aetiology
Exclusion
- Patients whose clinical course is entirely explained by
- Isolated prematurity
- Isolated unconjugated hyperbilirubinemia
- Infection or sepsis with expected response to therapy
- A previously confirmed genetic diagnosis that explains the clinical condition -
- Isolated transient neonatal tachypnoea
- Meconium aspiration syndrome
- Trauma
- Inability to source blood and buccal samples for DNA extraction from at least the mother and child
Key Trial Info
Start Date :
January 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06081075
Start Date
January 15 2024
End Date
December 1 2027
Last Update
May 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Auckland City Hospital
Auckland, New Zealand